P Das

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Clinical benefit of palliative radiation therapy in advanced gastric cancer
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Acta Oncol 47:421-7. 2008
  2. doi request reprint Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Pract Radiat Oncol 3:344-8. 2013
  3. doi request reprint Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Int J Radiat Oncol Biol Phys 88:301-5. 2014
  4. ncbi request reprint A watch-and-wait approach to the management of rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 27:962-8. 2013
  5. pmc ACR appropriateness criteria®  resectable rectal cancer
    William E Jones
    UT Health Science Center San Antonio, San Antonio, Texas, USA
    Radiat Oncol 7:161. 2012
  6. doi request reprint Rate of radiation therapy events in a large academic institution
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Coll Radiol 10:452-5. 2013
  7. pmc Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma
    Henry Mok
    Department of Radiation Oncology, The University of Texas, M, d, Anderson Cancer Center, Houston, Texas, USA
    Radiat Oncol 6:63. 2011
  8. ncbi request reprint Current treatment for localized anal carcinoma
    Prajnan Das
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Opin Oncol 19:396-400. 2007
  9. doi request reprint ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II
    Prajnan Das
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    J Am Coll Radiol 8:302-8. 2011
  10. ncbi request reprint Multimodality approaches to localized gastric cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas77030, USA
    J Natl Compr Canc Netw 8:417-25. 2010

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Clinical benefit of palliative radiation therapy in advanced gastric cancer
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Acta Oncol 47:421-7. 2008
    ..Local progression of advanced gastric cancer often manifests as bleeding, dysphagia/obstruction, or pain. We evaluated the magnitude and durability of palliation with radiotherapy (RT)...
  2. doi request reprint Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Pract Radiat Oncol 3:344-8. 2013
    ..The goal of this study was to determine the incidence and risk factors associated with gastric bleeding in patients treated with radiation therapy for intrahepatic cholangiocarcinoma...
  3. doi request reprint Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Int J Radiat Oncol Biol Phys 88:301-5. 2014
    ..The goal of this phase 1 trial was to determine the maximum tolerated dose (MTD) of concurrent capecitabine, bevacizumab, and erlotinib with preoperative radiation therapy for rectal cancer...
  4. ncbi request reprint A watch-and-wait approach to the management of rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 27:962-8. 2013
    ..Based on the available evidence, ideally a watch-and-wait approach for patients with rectal cancer should be pursued within the context of a prospective clinical trial...
  5. pmc ACR appropriateness criteria®  resectable rectal cancer
    William E Jones
    UT Health Science Center San Antonio, San Antonio, Texas, USA
    Radiat Oncol 7:161. 2012
    ..In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment...
  6. doi request reprint Rate of radiation therapy events in a large academic institution
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Coll Radiol 10:452-5. 2013
    ..The goals of this study were to determine the rate of radiation therapy patient events at a large academic institution and to evaluate temporal trends in this rate using statistical process control tools...
  7. pmc Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma
    Henry Mok
    Department of Radiation Oncology, The University of Texas, M, d, Anderson Cancer Center, Houston, Texas, USA
    Radiat Oncol 6:63. 2011
    ..Therefore, we performed a comprehensive dosimetric evaluation of IMRT compared to 3-dimensional conformal radiation therapy (3DCRT) in standard, preoperative treatment for rectal cancer...
  8. ncbi request reprint Current treatment for localized anal carcinoma
    Prajnan Das
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Opin Oncol 19:396-400. 2007
    ..Chemoradiation represents the standard of care for most patients with localized squamous cell carcinoma of the anal canal. This article reviews randomized trials and recent studies on chemoradiation for anal cancer...
  9. doi request reprint ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II
    Prajnan Das
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    J Am Coll Radiol 8:302-8. 2011
    ..This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists...
  10. ncbi request reprint Multimodality approaches to localized gastric cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas77030, USA
    J Natl Compr Canc Netw 8:417-25. 2010
    ..Other recent trials have evaluated the roles of preoperative chemoradiation and adjuvant chemotherapy. Multidisciplinary evaluation plays a crucial role in the management of these patients...
  11. ncbi request reprint Gastric and gastro-oesophageal cancer therapy
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Pharmacother 6:2805-12. 2005
    ..This article reviews recent trials on localised and metastatic gastric and gastro-oesophageal cancers...
  12. doi request reprint Long-term quality of life after radiotherapy for the treatment of anal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Cancer 116:822-9. 2010
    ..Radiotherapy is the current standard of care for patients with localized squamous cell cancer of the anal canal. The goal of the current study was to evaluate long-term quality of life (QoL) in patients after this treatment...
  13. pmc Reirradiation to the abdomen for gastrointestinal malignancies
    Waqar Haque
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiat Oncol 4:55. 2009
    ..Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen...
  14. doi request reprint Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation
    Prajnan Das
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 77:60-5. 2010
    ..To retrospectively determine rates of toxicity, freedom from local progression, and survival in rectal cancer patients treated with reirradiation...
  15. ncbi request reprint Staging, prognostic factors, and therapy of localized rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Curr Oncol Rep 11:167-74. 2009
    ..This article reviews recent studies on staging, prognostic factors, and therapy of localized rectal cancer...
  16. ncbi request reprint Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1750-5. 2007
    ..The objective of this study was to identify predictive factors for pathologic complete response and tumor downstaging after preoperative chemoradiation for rectal cancer...
  17. ncbi request reprint Predictors and patterns of recurrence after definitive chemoradiation for anal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:794-800. 2007
    ..To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer...
  18. ncbi request reprint Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis
    P Das
    Department of Radiation Oncology, U T M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Ann Oncol 17:785-93. 2006
    ..We derived model parameters from published studies and the Surveillance, Epidemiology and End Results (SEER) Program, and assumed that stage-shift produces a survival benefit...
  19. ncbi request reprint Combined modality therapy of localized gastric and esophageal cancers
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 4:375-82. 2006
    ..This article reviews the role of staging, surgery, and adjuvant and preoperative therapies in the management of localized gastric and esophageal cancers...
  20. ncbi request reprint Preoperative and adjuvant treatment of localized rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Curr Oncol Rep 8:167-73. 2006
    ..The roles of newer agents, such as capecitabine, oxaliplatin, and bevacizumab, are also discussed, and other key issues in the treatment of localized rectal cancer are reviewed...
  21. ncbi request reprint Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 29:219-24. 2006
    ..To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer...
  22. ncbi request reprint Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:1378-83. 2006
    ....
  23. pmc Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
    ..Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies...
  24. ncbi request reprint Clinical course of thoracic cancers in Hodgkin's disease survivors
    P Das
    Department of Radiation Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 16:793-7. 2005
    ..Hodgkin's disease survivors have a high risk of subsequently developing thoracic cancers. Our goal was to evaluate the prognosis and treatment outcomes of thoracic cancers after Hodgkin's disease...
  25. doi request reprint ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and II
    Prajnan Das
    The Universityof Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX 77030, USA
    J Am Coll Radiol 5:1054-66. 2008
    ..Representative clinical cases are presented, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists...
  26. doi request reprint Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome
    J D Schoenfeld
    Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Oncol 23:1813-8. 2012
    ..Hodgkin lymphoma (HL) survivors have an increased risk of secondary malignancies. We analyzed outcomes in patients with lung cancers following HL treatment...
  27. doi request reprint Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:3487-95. 2008
    ..We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma...
  28. ncbi request reprint Radiotherapy and Hodgkin's lymphoma
    Prajnan Das
    J Clin Oncol 23:8914; author reply 8914-6. 2005
  29. ncbi request reprint The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators
    A Sam Beddar
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Radiother Oncol 78:207-12. 2006
    ..To determine the effect of the curvature of Harrison-Anderson-Mick applicators on the dose distribution in high-dose-rate intraoperative radiation therapy (HDR-IORT)...
  30. ncbi request reprint Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 66:762-71. 2006
    ..The aim of this study was to determine the efficacy of capecitabine (Xeloda), an oral fluoropyrimidine, as a radiosensitizer in the neoadjuvant treatment of locally advanced rectal cancer (LARC)...
  31. ncbi request reprint Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2589-96. 2006
    ..Prognostic factors are inadequately defined for disease-free survival and overall survival in patients with LAPC who are receiving chemoradiation, so more definitive prognostic factors would be very useful for designing clinical trials...
  32. ncbi request reprint Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 110:47-55. 2007
    ....
  33. ncbi request reprint Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 70:735-43. 2008
    ..We retrospectively compared treatment outcomes in patients treated with pancreaticoduodenectomy alone versus those who received additional adjuvant CRT...
  34. doi request reprint Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy
    Valerie K Reed
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:741-7. 2008
    ..To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients...
  35. doi request reprint Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer
    Tse Kuan Yu
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1175-80. 2008
    ..To identify patterns of locoregional recurrence in patients treated with surgery and preoperative or postoperative radiotherapy or chemoradiation for rectal cancer...
  36. doi request reprint Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:167-72. 2008
    ....
  37. ncbi request reprint Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 29:562-7. 2006
    ..To evaluate the safety and efficacy of conformal radiotherapy (RT) of the dominant liver metastasis as palliative treatment of patients with unresectable colorectal cancer liver metastases...
  38. ncbi request reprint Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce
    Prajnan Das
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 54:698-702. 2002
    ..To identify events that precipitated a prostate-specific antigen (PSA) bounce and characterize the magnitude, duration, and time to PSA bounce after MRI-guided prostate brachytherapy...